Literature DB >> 6601285

Blood and lymph node T-lymphocyte subsets in non-Hodgkin lymphomas.

C Lindemalm, H Mellstedt, P Biberfeld, M Björkholm, B Christensson, G Holm, B Johansson, R Sundblad.   

Abstract

Blood and lymph node T-lymphocyte subpopulations have been studied in untreated non-Hodgkin lymphoma (NHL) patients and healthy controls. T-lymphocytes were determined by the E-rosette technique and by OKT3/LEU4 monoclonal antibodies; OKT4/LEU3 and OKT8/LEU2 monoclonal antibodies were used to identify T-cell subsets with helper/inducer and suppressor/cytotoxic activity, respectively. OKT4+ T-cells were low in patients, while OKT8+ T-cell numbers were normal. The OKT4+/OKT8+ blood lymphocyte ratio was below the normal range in about 50% of the patients. The ratio was higher in lymph nodes than in blood of patients and controls. The results may suggest that untreated NHL patients have a reduced pool of T-cells with phenotypic markers of OKT4/LEU3. Monoclonal blood B-lymphocytes were found in 45% of the cases. The presence of such cells in blood was frequently associated with a low OKT4+/OKT8+ ratio.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601285     DOI: 10.1111/j.1600-0609.1983.tb00636.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  12 in total

1.  Intra-tumoral cytolytic cells: pattern of distribution in B-cell non Hodgkin s lymphoma.

Authors:  S Perambakam; K Naresh; A Nerurkar; J Nadkarni
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.

Authors:  P Ragnhammar; G Masucci; J E Frödin; A L Hjelm; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  An immunohistochemical analysis of T cells in primary B cell malignant lymphoma of the brain.

Authors:  A Nishiyama; T Saito; S Abe; T Kumanishi
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Phenotypic and functional characterization of lymphocytes derived from normal and HIV-1-infected human lymph nodes.

Authors:  N Tedla; J Dwyer; P Truskett; D Taub; D Wakefield; A Lloyd
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

5.  Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  P Wersäll; G Masucci; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Activated T-cell subsets in benign lymphoid hyperplasias and B-cell non-Hodgkin's lymphomas.

Authors:  J I Diaz; M G Edinger; M H Stoler; R R Tubbs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

8.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

9.  The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).

Authors:  P Ragnhammar; I Magnusson; G Masucci; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

10.  Characterization of chronic lymphocytic leukemia (CLL) cells with low density of surface membrane bound immunoglobulins (smIg).

Authors:  E Kimby; B Axelsson; M Björkholm; J Gordon; G Holm; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.